1 Magnificent Growth Stock Down 55% to Buy Right Now, According to Wall Street

Zscaler generated record fiscal 2026 revenue of $3.35B, up 25% year over year and above its $3.33B forecast, while its Zero Trust Everywhere customer base rose 171% to 950. Fiscal 2027 guidance implies a slower ~17% revenue-growth rate due to near-term sales leadership disruption, though replacements have been made. Of 49 analysts tracked by The Wall Street Journal, 39 rate the stock buy or overweight and none rate it sell; the $207.40 average target implies 25% upside, with Zscaler trading at a 7.9x sales multiple versus a 13.2x three-year average.

Analysis

ZS's discount is not automatically a mispricing: PANW and CRWD command premiums partly because investors view their platforms as consolidators with broader cross-sell engines, whereas ZS must prove that AI-agent security expands wallet share rather than becomes a feature bundled into existing SSE/SASE contracts. The investable variable is therefore net-new annual contract value and large-customer expansion, not generic AI-security demand. A sustained acceleration in billings/RPO and in modules per customer would support multiple expansion; absent that, the lower sales multiple may simply price a structurally slower growth profile.

The near-term setup is asymmetric only if execution concerns are already embedded. Over the next 1-3 months, sales-leadership transition and fiscal-year guidance cadence can cap upside even if security spending remains resilient; channel checks on federal/large-enterprise pipeline conversion and sales-rep attrition are the key missing data. In 6-18 months, agentic-AI deployments could shift security budgets toward identity, data controls and runtime monitoring, benefiting ZS but also strengthening CRWD's identity/endpoint position and PANW's platform-bundling leverage.

Consensus appears too focused on headline valuation comparisons. ZS can rerate materially without matching peer multiples, but a rerating requires evidence that operating leverage survives incremental go-to-market investment; otherwise, growth deceleration plus elevated stock-based compensation can leave free-cash-flow per share lagging revenue. The principal falsifier is a second consecutive guide-down or billings growth falling below revenue growth, which would signal weakened demand rather than a temporary sales disruption.

Key Decisions for Investors

• Initiate a 6-9 month long ZS / short PANW pair only after the next earnings release confirms billings or RPO reacceleration and FY revenue guidance is maintained or raised. Target 15-25% relative upside from ZS multiple normalization; exit if ZS guides growth below the current mid-teens trajectory or materially increases sales hiring expense without pipeline conversion.
• For directional exposure, buy ZS shares in tranches around post-earnings volatility rather than chase pre-results. Size modestly until enterprise sales-transition data are visible; upside requires both execution stabilization and a higher EV/sales multiple, while downside remains substantial if guidance is reset.
• Use CRWD as the preferred hedge for an AI-security spending disappointment only if its endpoint/identity cross-sell metrics remain intact. A long ZS/short CRWD trade is not attractive today: CRWD's premium can persist if buyers consolidate toward a broader security platform.
• Set a research alert for large-deal commentary, remaining-performance-obligation growth, and net-retention/module-adoption disclosures at the next two ZS reports. These are the decisive indicators of whether AI offerings are generating incremental budget rather than being absorbed into renewals.